Summary:
Click image to enlargeA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)
Qualified Participants Must:
• Male/Female 18-74 years of age
•
Heva been diagnosed with Bipolar I or Bipolar II disorder
•
Are currently having a majprdepressive episode that started at least 2 weeks ago, but no more than 6 months ago
•
Have previously had at least 1 bipolar manic or hypomanic episode
Qualified Participants May Receive:
Qualified participants will be compensated for time and travel